1. Home
  2. EPD vs MRNA Comparison

EPD vs MRNA Comparison

Compare EPD & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enterprise Products Partners L.P.

EPD

Enterprise Products Partners L.P.

SELL

Current Price

$37.39

Market Cap

82.4B

Sector

Utilities

ML Signal

SELL

Logo Moderna Inc.

MRNA

Moderna Inc.

SELL

Current Price

$207.04

Market Cap

91.2B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
EPD
MRNA
Founded
1968
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Natural Gas Distribution
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
82.4B
91.2B
IPO Year
1998
2018

Fundamental Metrics

Financial Performance
Metric
EPD
MRNA
Price
$37.39
$207.04
Analyst Decision
Buy
Hold
Analyst Count
23
23
Target Price
$41.67
★ $165.32
AVG Volume (30 Days)
3.7M
★ 12.5M
Earning Date
10-29-2026
11-06-2026
Dividend Yield
★ 5.98%
N/A
EPS Growth
★ 106.96
21.77
EPS
★ 2.38
N/A
Revenue
★ $52,596,000,000.00
$19,263,000,000.00
Revenue This Year
$26.20
$24.20
Revenue Next Year
$4.90
$11.31
P/E Ratio
$15.73
★ N/A
Revenue Growth
N/A
★ 4.29
52 Week Low
$31.35
$22.28
52 Week High
$40.17
$280.80

Technical Indicators

Market Signals
Indicator
EPD
MRNA
Relative Strength Index (RSI) 50.90 44.64
Support Level $36.96 $181.02
Resistance Level $38.84 $254.48
Average True Range (ATR) 0.75 17.25
MACD 0.05 -5.34
Stochastic Oscillator 34.48 1.40

Price Performance

Historical Comparison
EPD
MRNA

About EPD Enterprise Products Partners L.P.

Enterprise Products Partners is a master limited partnership that transports and processes natural gas, natural gas liquids, crude oil, refined products, and petrochemicals. It is one of the largest midstream companies, with operations servicing most producing regions in the continental US. Enterprise is particularly dominant in the NGL market and is one of the few MLPs that provide midstream services across the full hydrocarbon value chain.

About MRNA Moderna Inc.

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Share on Social Networks: